Compare BioNTech SE - ADR (BNTX) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs T-Mobile Us Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while T-Mobile Us Inc trades at $176.96 (market cap $191.56B). The key difference: T-Mobile Us Inc is far larger — about 8.2× BioNTech SE - ADR's market cap, and T-Mobile Us Inc pays a 2.28% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TMUS | |
|---|---|---|
Market Cap | $23.31B | $191.56B |
Sector | Health | Media |
52-Week High | $119.34 | $259.01 |
52-Week Low | $83.89 | $167.65 |
Enterprise Value | $6.60B | $308.17B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
TMUS trades at $177.02, down 0.64% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.99 actual vs. $2.59 expected, and raised its free cash flow outlook. Revenue growth remains robust, reaching $88.31 billion in 2025, though net income dipped slightly to $10.99 billion. Recent news includes the completion of an $2.9 billion spectrum sale to Grain Management and competitive concerns from SpaceX's Starlink Mobile expansion.
The outlook for TMUS is mixed; strong fundamentals and analyst bullishness with an $233.20 price target suggest upside, but technical bearishness and competitive threats from new entrants like SpaceX pose risks. Earnings momentum and dividend growth support long-term value, yet near-term volatility may persist due to market sentiment and industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
